Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor

摘要: Activating mutations in the epidermal growth factor receptor ( EGFR ) are detected approximately 10% of Caucasian and up to 50% Asian patients with non-small cell lung cancer (NSCLC).1 EGFR-tyrosine kinase inhibitors (TKIs) constitute preferred first-line treatment for these patients. Unfortunately, all eventually develop resistance EGFR-TKI after a median 13 months.2 Several different mechanisms have been demonstrated biopsies recurrent tumours treatment. Among T790M secondary mutation on exon 20 amplification alternative pathways such as hepatocyte (MET) human 2 (HER2), but also morphological changes epithelial-to-mesenchymal transition transformation small (SCLC) phenotype.2 Here we report case squamous carcinoma (SqCC) phenotype. To best our knowledge, …